Company news

Xeris Biopharma Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

March 9, 2022

Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

March 9, 2022

Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

March 3, 2022

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 8, 2022

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

January 30, 2022

Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

January 17, 2022

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

January 5, 2022

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

January 2, 2022

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

December 29, 2021

Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

December 15, 2021

Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

November 9, 2021

Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

November 1, 2021

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

October 24, 2021

Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

October 4, 2021

Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 16, 2021

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

September 13, 2021

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

September 7, 2021

Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

August 31, 2021

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

August 30, 2021

Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

August 29, 2021

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia

August 22, 2021

Xeris Pharmaceuticals Strengthens Its Patent Estate

August 18, 2021

Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®

August 12, 2021

Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

August 10, 2021

Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights

August 4, 2021

Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

July 28, 2021

Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

July 28, 2021

Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success

July 27, 2021

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

July 18, 2021

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

May 23, 2021

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

May 23, 2021

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

May 23, 2021

Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

May 12, 2021

Xeris Pharmaceuticals to Webcast Upcoming Presentations

May 9, 2021

Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

May 5, 2021

Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank

May 5, 2021

Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

April 28, 2021

Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering

March 10, 2021

Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights

March 8, 2021

Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021

March 1, 2021

Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations

February 17, 2021

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

February 11, 2021

Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

January 4, 2021

Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority

December 21, 2020

Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

December 10, 2020

Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

November 8, 2020

Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

November 1, 2020

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

October 19, 2020

Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 7, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks